Clinical Trial

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-05-09 -> 2026-09-18 2026-06-19
Trial Details
NCT Number NCT06625177
Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC
Conditions Vitiligo
Enrollment 38 participants
Start Date 2024-11-11
Primary Completion 2026-09-18 (estimated)
Study Completion 2027-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-18